Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Jun 07, 2018 1:02pm
230 Views
Post# 28140382

RE:RE:RE:RE:RE:RE:RE:RE:Quick summary points from a very busy guy

RE:RE:RE:RE:RE:RE:RE:RE:Quick summary points from a very busy guy"I dont really agree with what you describe as faulty human nature."

If we are talking about human nature, good or bad, then I expect that if the story remains positive then both management groups are going to struggle to resist the urge to share. Both have done it already, Thera volunteered the number in the cc, Taimed to some extent focused by negative reaction to the monthly revenue. I expect they'll do it again for many reason. Whether at an investor conference, in a press interview or on a Q cc if they've just passed a significant milestone in patient numbers then the urge to back up the good news story with a liitle nugget is going to be too much. No matter how disciplined and cautious they are.


Bullboard Posts